Stem Cell Therapy Market Booms to US$ 63.23 Billion by 2031, Led by Mesoblast, Novartis & CRISPR Therapeutics With North America Holding 41% Share

The Global Stem Cell Therapy Market was valued at US$ 15.15 billion in 2024 and is projected to reach US$ 63.23 billion by 2031, growing at a CAGR of 22.6% during the forecast period. Growth is driven by rising cases of chronic and degenerative diseases, increasing demand for regenerative medicine, and continuous advancements in stem cell harvesting, processing, and therapeutic delivery technologies.

The market is also gaining strong momentum due to expanding clinical trials, government funding, and commercialization of allogeneic stem cell products, which offer greater scalability and standardization. Stem cell therapies are increasingly being adopted for cardiovascular, neurological, autoimmune, and orthopedic applications, strengthening the market's position as a leading segment in advanced therapeutics.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/stem-cell-therapy-market?sai-v

Stem Cell Therapy Market refers to the industry focused on developing and delivering treatments that use stem cells to repair, replace, or regenerate damaged tissues and support healing in various medical conditions

Key Developments

United States
✅ August 2025: U.S. biotech companies expanded clinical trials for allogeneic stem cell therapies targeting musculoskeletal disorders, with new Phase II results showing improved tissue regeneration outcomes.

✅ June 2025: American research institutes launched large-scale programs to develop stem-cell-derived cardiomyocytes for heart failure treatment, accelerating commercialization pathways for regenerative cardiac therapies.

✅ March 2025: U.S. manufacturers introduced next-generation cryopreservation systems designed to enhance viability and shelf stability of stem cell products during transport and long-term storage.

Japan
✅ September 2025: Japanese pharmaceutical firms advanced development of iPSC-derived cell therapies for Parkinson's disease, expanding domestic clinical research capacity for neurological applications.

✅ May 2025: Japan's regenerative medicine centers deployed automated cell processing platforms to improve the consistency and scalability of stem cell manufacturing.

✅ February 2025: Researchers in Japan developed new quality-control biomarkers to evaluate the safety and purity of stem cell-based therapeutics before clinical use.

Mergers & Acquisitions
United States
✅ April 2025: A U.S. regenerative medicine company acquired a stem cell processing technology provider to enhance its clinical-scale manufacturing capabilities for allogeneic therapies.

Japan
✅ March 2025: A Japanese biotech firm formed a strategic partnership with a domestic hospital network to co-develop stem cell therapy clinical programs for orthopedic and neurological disorders.

✅ January 2025: A Japan-based cell therapy developer entered a collaboration with a U.S. biopharma company to expand global commercialization of iPSC-derived therapeutic products.

Key Players:
Mesoblast Ltd | Lineage Cell Therapeutics, Inc. | BlueRock Therapeutics LP | Orchard Therapeutics plc | Vericel Corporation | CRISPR Therapeutics AG | Fate Therapeutics, Inc. | Novartis AG | Bristol-Myers Squibb (Juno Therapeutics) | Bluebird Bio, Inc. | MEDIPOST Co., Ltd. | Anterogen Co., Ltd. | CorestemChemon Inc. | Pharmicell Co., Ltd. | JCR Pharmaceuticals Co., Ltd.

Key Highlights :
• Mesoblast Ltd - 14.5% share of the global stem cell therapy market, driven by its advanced mesenchymal stem-cell platforms and broad pipeline in inflammatory and cardiovascular indications.

• Novartis AG - 13.2% share, supported by its scale in engineered cell therapy, allogeneic platforms, and strong position in clinical-stage programs.

• CRISPR Therapeutics AG - 11.1% share, backed by its gene-edited cell therapies, CRISPR-based platforms, and partnerships in regenerative medicine.

• Fate Therapeutics, Inc. - 9.7% share, propelled by its off-the-shelf iPSC-derived natural killer (NK) and T-cell products.

• Lineage Cell Therapeutics, Inc. - 8.4% share, supported by its differentiated progenitor cell therapies for neurological and ocular diseases.

• BlueRock Therapeutics LP - 7.6% share, driven by its iPSC-derived regenerative platforms for cardiac and neurological repair.

• Vericel Corporation - 6.5% share, maintained through its licensed cell therapy products (like MACI) and regenerative musculoskeletal applications.

• Orchard Therapeutics plc - 5.8% share, fueled by its gene-therapy coupled with cell therapy approaches and rare disease pipelines.

• Bluebird Bio, Inc. - 5.0% share, influenced by its lentiviral and gene-corrected stem cell programs in hematology and rare diseases.

• MEDIPOST Co., Ltd. - 4.3% share, supported by its allogeneic MSC product Cartistem and regenerative medicine pipeline in Asia.

• Anterogen Co., Ltd. - 3.7% share, driven by its cord-derived MSC therapies and localized clinical development in East Asia.

• Pharmicell Co., Ltd. - 2.9% share, contributing through its cell therapy products in cardiovascular disease and regenerative applications.

• JCR Pharmaceuticals Co., Ltd. - 2.4% share, supported by its MSC-based therapies and partnerships in Asia.

• CorestemChemon Inc. - 1.9% share, fueled by its niche research in neuro-regeneration using stem-cell-based approaches.

• Bristol-Myers Squibb (Juno Therapeutics) - 1.5% share, driven by its investment in CAR-T and engineered cell therapy platforms (via Juno).

Purchase this report before year-end and unlock an exclusive 30% discount: https://www.datamintelligence.com/buy-now-page?report=stem-cell-therapy-market?sai-v
(Purchase 2 or more Reports and get 50% Discount)

Market Drivers
• Rising prevalence of chronic diseases, including orthopedic disorders, cardiovascular conditions, and neurodegenerative diseases, is accelerating demand for stem cell-based treatments.

• Increasing use of regenerative medicine for tissue repair, wound healing, and immune modulation is boosting market adoption globally.

• Expanding number of clinical trials focused on stem cell therapies for diabetes, spinal cord injuries, and autoimmune disorders is strengthening commercial prospects.

• Advancements in cell manufacturing, cryopreservation, and genetic engineering are enabling more effective and accessible therapeutic applications.

• Growing investments from governments and private companies in cell banks, R&D facilities, and GMP-certified production centers are supporting market expansion.

Industry Developments
• September 2025 (US): Researchers developed optimized allogeneic stem cell formulations offering improved immune compatibility and enhanced therapeutic outcomes.

• July 2025 (South Korea): Biopharma companies introduced next-generation stem cell-derived exosome therapies targeting inflammatory and degenerative disorders.

• May 2025 (Germany): New automated stem cell bioprocessing systems were launched to support large-scale clinical manufacturing and reduce production bottlenecks.

• April 2025 (Japan): Hospitals and research institutes expanded trials using induced pluripotent stem cells (iPSCs) for retinal, cardiac, and neurological treatments.

Regional Insights
• North America: US$ 5.4 billion with 41 percent share. Growth is driven by "high clinical trial activity, strong regulatory support for regenerative medicine, and increasing adoption of advanced cell therapies across specialized treatment centers."

• Europe: US$ 3.8 billion with 29 percent share. Expansion is supported by "well-established healthcare infrastructure, strong government funding for cell therapy research, and rising approvals for regenerative treatments."

• Asia Pacific: US$ 3.2 billion with 24 percent share. Growth is fueled by "rapid expansion of stem cell manufacturing facilities, increasing medical tourism, and supportive national policies for regenerative medicine."

• Latin America: US$ 0.6 billion with 4 percent share. Demand is rising due to "growing adoption of stem cell therapies in private clinics, rising chronic disease burden, and increasing investments in healthcare modernization."

• Middle East and Africa: US$ 0.4 billion with 3 percent share. Growth is driven by "expanding regenerative medicine centers, rising interest in cell-based orthopedics and cosmetic applications, and government initiatives to attract medical tourism."

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/stem-cell-therapy-market?sai-v

Key Segments

By Therapy Type
Autologous therapy uses a patient's own stem cells, reducing the risk of immune rejection and complications. It is widely used in orthopedic repair, neurological treatments, and regenerative wound healing. This approach supports personalized medicine and offers faster recovery with minimal ethical concerns.

Allogeneic therapy uses stem cells from a donor, enabling large-scale production and standardized treatments. It is increasingly adopted for autoimmune diseases, cardiovascular repair, and inflammatory disorders. Its scalability makes it suitable for widespread clinical use and off-the-shelf therapeutic products.

By Cell Source
Adipose-derived cells are popular due to easy extraction, high cell yield, and strong regenerative potential. They are frequently used in musculoskeletal repair, wound healing, and inflammatory disease management.

Bone Marrow-Derived Mesenchymal Stem Cells
Bone marrow cells are among the most established sources for stem cell therapy. They provide strong clinical outcomes in orthopedic applications, neurological repair, and autoimmune disease treatment due to their proven safety and differentiation ability.

Cord Blood / Embryonic Stem Cells
Cord blood and embryonic stem cells offer high pluripotency and strong regenerative capacity. They are used in advanced therapies for neurological conditions, metabolic disorders, cardiovascular repair, and immune-related diseases.

Others
Includes induced pluripotent stem cells (iPSCs), peripheral blood stem cells, and tissue-specific progenitor cells used in research and emerging clinical applications.

By Therapeutic Application
Musculoskeletal Disorders
Stem cell therapy is widely adopted for cartilage regeneration, tendon repair, osteoarthritis treatment, and bone healing. It supports faster recovery and improved mobility in orthopedic conditions.

Neurological Disorders
Applications include stroke recovery, spinal cord injury repair, Parkinson's disease, and neurodegenerative conditions. Regenerative therapies aim to restore lost neural function and slow disease progression.

Autoimmune Diseases
Stem cell treatments help reset immune function and reduce disease activity in conditions like rheumatoid arthritis, lupus, and multiple sclerosis.

Cardiovascular Diseases
Therapies support regeneration of damaged heart tissue, enhance blood vessel formation, and improve outcomes in heart failure, myocardial infarction, and ischemic disorders.

Wounds & Surgeries
Stem cells accelerate healing, reduce scarring, and support tissue regeneration in chronic wounds, burns, and post-surgical recovery.

Inflammatory Disorders
Used to reduce systemic inflammation and modulate immune responses in chronic inflammatory diseases.

Others
Includes applications in metabolic disorders, organ repair, and emerging regenerative medicine therapies.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.